Infliximab: a review of its use in the management of rheumatoid arthritis.
about
Drug-disease interactions: reduced beta-adrenergic and potassium channel antagonist activities of sotalol in the presence of acute and chronic inflammatory conditions in the ratInfliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective studyBiologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritisUpdated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000)The pharmacological management of drug-induced rheumatic disorders.Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001)Soluble cytokine receptors in biological therapy.Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).Biologic therapies for juvenile arthritisSkin reactions related to treatment with anticytokines, membrane receptor inhibitors and monoclonal antibodies.Chronic obstructive pulmonary disease * 12: New treatments for COPDUpdated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.Novel targets for the treatment of endometriosis.Infliximab in the treatment of Crohn's disease.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007The use of TNF-alpha blocking agents in rheumatoid arthritis: an update.Infliximab in the treatment of rheumatoid arthritisInfliximab for the treatment of plaque psoriasis.Inhibition of cytokine response to TLR stimulation and alleviation of collagen-induced arthritis in mice by Schistosoma japonicum peptide SJMHE1.Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs.Management of ankylosing spondylitis with infliximab.Fibroblast paracrine TNF-α signaling elevates integrin A5 expression in idiopathic pulmonary fibrosis (IPF).Infliximab Biosimilars: A Promising but Unusual Treatment for Mycobacterial Immune Reconstitution Inflammatory Syndrome in Human Immunodeficiency Virus-Infected Patients.Effect of calcium hydroxide on proinflammatory cytokines and neuropeptides.Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis.An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease.Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases.Infliximab efficacy in pediatric ulcerative colitis.Localized expression of an anti-TNF single-chain antibody prevents development of collagen-induced arthritis.Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management.Expression of Tumor Necrosis Factor Receptor 2 Characterizes TLR9-Driven Formation of Interleukin-10-Producing B Cells.Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: Management.Rapidly aggravated Mycobacterium avium infection in a patient with rheumatoid arthritis treated with infliximab.Tumor necrosis factor regulation of apoptosis in mouse preimplantation embryos and its antagonism by transforming growth factor alpha/phosphatidylionsitol 3-kinase signaling system.
P2860
Q24673703-EE5F383E-32B3-4B09-801B-52A8C1EED80CQ24798468-84B0186F-072B-4629-819C-90B4154F3F19Q26852235-C9796B19-B3FD-478B-8A24-96A1B70ADD82Q34071238-117CFB21-41DE-4B01-A187-19F92D25972DQ34515405-6ECCA233-CD2C-4741-9D3F-D7A5DFB711F6Q34560553-5FD83F3E-4423-4266-B186-8E2274894C1BQ34779777-C67350C6-BD56-47C8-BAC5-C33BF5531D58Q34962946-ADB6FDDA-97EC-47A3-A3AB-53022F3261CFQ35070925-1C1E39E8-C71F-4AA5-A598-82F433628B75Q35208404-2872CBD1-57BE-4C19-866D-C7A834629BB1Q35208742-C460E402-7D48-4CFD-BF71-F034B5D87EE2Q35579352-584AD4D2-AF3D-45F4-BBD9-76CF170EEB7EQ35579517-49CAA5B5-4E71-4BEE-B126-BCF05127ECEBQ35638252-E475EB64-A118-4E1A-9043-BDBB00307A38Q35911132-0A16E9AF-FCA7-41E4-A4FC-40A609DDE6F1Q35919228-84D00529-E313-40DA-89FF-E59227D59E3FQ36171750-83F5FD08-44D2-4B85-BEDD-DA7D9C8FA9DFQ36916918-3C308F0B-21D8-429C-9617-B0A60EA95CF0Q37303230-4562298A-A9BA-462D-833B-DDB06C03DF67Q37307554-676317C3-7EA0-4097-8D93-5E581182E77AQ37662876-575A8A36-17FF-4C93-9469-E35528BE812BQ37786627-8B3DC03D-FA6F-4291-B1B6-3BDA07CDC0A3Q38357886-DFC95876-9DC3-4DC6-A3B3-832B98A12CC7Q38993236-E9BB6902-4BAF-4B39-B88A-FF72623FA539Q41090863-B32C3CFE-62D1-48AA-9533-E779662283BCQ41694401-E1A7EFB7-A063-485C-8D02-0B3841BB7985Q42182952-7188435C-337C-492A-9352-677EA09B907CQ42955185-2C4F0266-3353-49C7-85B3-8272F6CA0D02Q44006206-1DEB975E-7389-4E2D-9CE9-126E5122DFDCQ44516630-7B7EEC8D-F34E-437B-8468-9B7A35F50E3FQ45285885-DB62527B-ACB1-4F3A-BBC5-A7C963B3918DQ45863664-8A40E740-9EF8-413A-A07D-7E85627E05BBQ49508046-CD5D4941-57F6-4B50-9333-01E94836160EQ49534097-B9911ECB-9630-455B-A292-780C55A7CACFQ50098937-B4001A26-951C-4116-BEEB-F7A31486141CQ51781595-79E5F9FC-7808-474F-AE3E-290AEDE04F62Q51998718-D579AF18-D122-43AD-AD50-4FC67E218AAA
P2860
Infliximab: a review of its use in the management of rheumatoid arthritis.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Infliximab: a review of its use in the management of rheumatoid arthritis.
@ast
Infliximab: a review of its use in the management of rheumatoid arthritis.
@en
Infliximab: a review of its use in the management of rheumatoid arthritis.
@en-gb
type
label
Infliximab: a review of its use in the management of rheumatoid arthritis.
@ast
Infliximab: a review of its use in the management of rheumatoid arthritis.
@en
Infliximab: a review of its use in the management of rheumatoid arthritis.
@en-gb
prefLabel
Infliximab: a review of its use in the management of rheumatoid arthritis.
@ast
Infliximab: a review of its use in the management of rheumatoid arthritis.
@en
Infliximab: a review of its use in the management of rheumatoid arthritis.
@en-gb
P1433
P1476
Infliximab: a review of its use in the management of rheumatoid arthritis.
@en
P2093
P304
P356
10.2165/00003495-200059060-00010
P577
2000-06-01T00:00:00Z
P6179
1030720854